Ted M Ross1, Chyongchiou Jeng Lin2, Mary Patricia Nowalk2, Hsin-Hui Huang2, Sarah M Spencer3, David K Shay3, Suryaprakash Sambhara3, Maria E Sundaram4, Thomas Friedrich5, Sandy Sauereisen6, Chalise E Bloom1, Richard K Zimmerman2. 1. Center for Vaccine Research; University of Pittsburgh; Pittsburgh, PA USA; Vaccine & Gene Therapy Institute of Florida; Port Saint Lucie, FL USA. 2. Department of Family Medicine; School of Medicine; University of Pittsburgh; Pittsburgh, PA USA. 3. Centers for Disease Control and Prevention; Influenza Division/NCIRD; Atlanta, GA USA. 4. Marshfield Clinic Research Foundation; Marshfield, WI USA. 5. Department of Pathobiological Sciences; University of Wisconsin School of Veterinary Medicine; Madison, WI USA; Wisconsin National Primate Research Center; Madison, WI USA. 6. UPMC St. Margaret's Family Medicine Residency, Pittsburgh, PA USA.
Abstract
BACKGROUND: Concerns about influenza vaccine effectiveness in older adults and the role of influenza strains encountered earlier in life led to this study. METHODS: Antibody responses against antigens in the 2011-2012 influenza vaccine at 21 days post vaccination were analyzed in 264 individuals aged 50-80 years. At Days 0 and 21, sera were tested for hemagglutination-inhibition titers against these vaccine strains and at Day 0 against a panel of 15 historical seasonal strains.: RESULTS: The proportions of participants with seroprotective titers ≥1:40 to the vaccine strains at Days 0 and 21, respectively, were 37% and 66% for A(H1N1) and 28% and 63% for A(H3N2). An increasing number of responses ≥1:40 against historical strains was associated with seroprotective responses after vaccination among participants with a titer<1:40 at Day 0 for A(H1N1) and A(H3N2) vaccine strains (P<0.01). In multivariable regression analyses among those with Day 0 titer<1:40, after controlling for age, sex, race, site and diabetes, Day 21 titers ≥ 1:40 for the vaccine A strains were significantly more likely as the number of seroprotective responses against historical strains increased (A(H1N1) odds ratio [OR] = 1.41, 95% confidence interval [CI] = 1.09-1.82 and A(H3N2) OR = 1.32, 95% CI = 1.07-1.62). The likelihood of seroconversion was significantly higher with an increasing number of responses to historical strains for A(H3N2) only (OR = 1.24, 95% CI = 1.01-1.52). Seroconversion was significantly less likely as Day 0 vaccine strain titers increased. CONCLUSIONS: Seroprotective titers after influenza vaccination increased as the number of responses to historical strains increased.
BACKGROUND: Concerns about influenza vaccine effectiveness in older adults and the role of influenza strains encountered earlier in life led to this study. METHODS: Antibody responses against antigens in the 2011-2012 influenza vaccine at 21 days post vaccination were analyzed in 264 individuals aged 50-80 years. At Days 0 and 21, sera were tested for hemagglutination-inhibition titers against these vaccine strains and at Day 0 against a panel of 15 historical seasonal strains.: RESULTS: The proportions of participants with seroprotective titers ≥1:40 to the vaccine strains at Days 0 and 21, respectively, were 37% and 66% for A(H1N1) and 28% and 63% for A(H3N2). An increasing number of responses ≥1:40 against historical strains was associated with seroprotective responses after vaccination among participants with a titer<1:40 at Day 0 for A(H1N1) and A(H3N2) vaccine strains (P<0.01). In multivariable regression analyses among those with Day 0 titer<1:40, after controlling for age, sex, race, site and diabetes, Day 21 titers ≥ 1:40 for the vaccine A strains were significantly more likely as the number of seroprotective responses against historical strains increased (A(H1N1) odds ratio [OR] = 1.41, 95% confidence interval [CI] = 1.09-1.82 and A(H3N2) OR = 1.32, 95% CI = 1.07-1.62). The likelihood of seroconversion was significantly higher with an increasing number of responses to historical strains for A(H3N2) only (OR = 1.24, 95% CI = 1.01-1.52). Seroconversion was significantly less likely as Day 0 vaccine strain titers increased. CONCLUSIONS: Seroprotective titers after influenza vaccination increased as the number of responses to historical strains increased.
Entities:
Keywords:
Human influenza; antibodies; immune response; immunogenicity
Authors: Joon Young Song; Hee Jin Cheong; In Sook Hwang; Won Suk Choi; Yu Mi Jo; Dae Won Park; Geum Joo Cho; Taik Gun Hwang; Woo Joo Kim Journal: Vaccine Date: 2010-04-13 Impact factor: 3.641
Authors: Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Justin Lessler; Steven Riley; Jonathan M Read; Shuying Wang; Huachen Zhu; Gavin J D Smith; Yi Guan; Chao Qiang Jiang; Derek A T Cummings Journal: PLoS Pathog Date: 2012-07-19 Impact factor: 6.823
Authors: Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross Journal: J Virol Date: 2016-04-14 Impact factor: 5.103
Authors: Brendan Flannery; Catherine Smith; Rebecca J Garten; Min Z Levine; Jessie R Chung; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary Patricia Nowalk; Marie R Griffin; H Keipp Talbot; John J Treanor; David E Wentworth; Alicia M Fry Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Sarah F Andrews; Yunping Huang; Kaval Kaur; Lyubov I Popova; Irvin Y Ho; Noel T Pauli; Carole J Henry Dunand; William M Taylor; Samuel Lim; Min Huang; Xinyan Qu; Jane-Hwei Lee; Marlene Salgado-Ferrer; Florian Krammer; Peter Palese; Jens Wrammert; Rafi Ahmed; Patrick C Wilson Journal: Sci Transl Med Date: 2015-12-02 Impact factor: 17.956
Authors: Min Z Levine; Judith M Martin; F Liaini Gross; Stacie Jefferson; Kelly Stefano Cole; Crystal Ann Archibald; Mary Patricia Nowalk; Michael Susick; Krissy Moehling; Sarah Spencer; Jessie R Chung; Brendan Flannery; Richard K Zimmerman Journal: Clin Vaccine Immunol Date: 2016-10-04
Authors: Ivette A Nuñez; Michael A Carlock; James D Allen; Simon O Owino; Krissy K Moehling; Patricia Nowalk; Michael Susick; Kensington Diagle; Kristen Sweeney; Sophia Mundle; Thorsten U Vogel; Simon Delagrave; Moti Ramgopal; Richard K Zimmerman; Harry Kleanthous; Ted M Ross Journal: PLoS One Date: 2017-11-01 Impact factor: 3.240
Authors: Christine M D Lingblom; Sangeeta Kowli; Nithya Swaminathan; Holden T Maecker; Stacie L Lambert Journal: J Transl Med Date: 2018-06-05 Impact factor: 5.531